Sandoz Group AG (XSWX:SDZ) Other Operating Expense: CHF225 Mil (TTM As of Dec. 2025)


XSWX:SDZ Sandoz Group AG XSWX:SDZ
11 GF Score
Price CHF67.78
! 6 Warning Signs
View Full Analysis

What is Sandoz Group AG Other Operating Expense?

Sandoz Group AG XSWX:SDZ -1.20% 11 Other Operating Expense is CHF225 Mil as of Dec. 2025. GuruFocus rates XSWX:SDZ with a GF Score™ of 11/100. The stock has 6 warning signs investors should review.

Sandoz Group AG's Other Operating Expense for the six months ended in Dec. 2025 was CHF133 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was CHF225 Mil.

Sandoz Group AG's quarterly Other Operating Expense declined from Dec. 2024 (CHF839 Mil) to Jun. 2025 (CHF92 Mil) but then increased from Jun. 2025 (CHF92 Mil) to Dec. 2025 (CHF133 Mil).

Sandoz Group AG's annual Other Operating Expense increased from Dec. 2023 (CHF756 Mil) to Dec. 2024 (CHF1,118 Mil) but then declined from Dec. 2024 (CHF1,118 Mil) to Dec. 2025 (CHF223 Mil).

Sandoz Group AG Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Sandoz Group AG's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sandoz Group AG Other Operating Expense Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Other Operating Expense
166.76 755.84 1,118.07 223.13

Sandoz Group AG Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Operating Expense Get a 7-Day Free Trial 491.21 279.76 839.00 91.89 133.08
XSWX:SDZ
11GF Score
Sandoz Group AG XSWX:SDZ
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sandoz Group AG Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF225 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of CHF225 Mil mean?
Sandoz Group AG (XSWX:SDZ) has a Other Operating Expense of CHF225 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Sandoz Group AG and its competitors.
Is Sandoz Group AG's Other Operating Expense too high?
Sandoz Group AG's current Other Operating Expense is CHF225 Mil. Overall, Sandoz Group AG has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's Other Operating Expense compare to ZTS and UTHR?
Sandoz Group AG's Other Operating Expense of CHF225 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Sandoz Group AG and its competitors. Sandoz Group AG's current Other Operating Expense is CHF225 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Sandoz Group AG (XSWX:SDZ) has a current Other Operating Expense of CHF225 Mil. The current Other Operating Expense is CHF225 Mil. Sandoz Group AG's overall GF Score™ is 11/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Sandoz Group AG (XSWX:SDZ), the current Other Operating Expense is CHF225 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sandoz Group AG Business Description

Address Centralbahnstrasse 4, Basel, CHE, 4051
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
11GF Score

Get the complete analysis for XSWX:SDZ

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF67.78
Price